PeptidePedia The community reference

Glucagon: difference between revisions

Diff·revision 16 → 17·11:44, 8 May 2025

Difference between revision 16 and revision 17 of Glucagon. 3 lines changed; the page grew by 288 bytes.

Revision 16 — 20:23, 9 Apr 2025
BPC_Bramwell (talk)
sentence case in headings per PP:MOS
5,754 bytes ±0
Revision 17 — 11:44, 8 May 2025
FreightFenna (talk)
reorder the analogues chronologically rather than alphabetically
6,042 bytes +288
41The obstacle is that the same agonism raises blood glucose. The design solution is a fixed intramolecular ratio: [[Retatrutide|retatrutide]] engages GIP, GLP-1 and glucagon receptors; [[Survodutide|survodutide]] engages glucagon and GLP-1 receptors; efinopegdutide engages glucagon and GLP-1 receptors with a different balance and has been studied principally for hepatic fat. In each case the GLP-1 component is dosed sufficiently to dominate the net glycaemic effect.41The obstacle is that the same agonism raises blood glucose. The design solution is a fixed intramolecular ratio: [[Retatrutide|retatrutide]] engages GIP, GLP-1 and glucagon receptors; [[Survodutide|survodutide]] engages glucagon and GLP-1 receptors; efinopegdutide engages glucagon and GLP-1 receptors with a different balance and has been studied principally for hepatic fat. In each case the GLP-1 component is dosed sufficiently to dominate the net glycaemic effect.
4242
+43Reported weight loss with the triple agonist at the highest doses studied exceeds that reported for GLP-1 monotherapy, though cross-trial comparison of this kind is unreliable and the programmes differ in population, duration and escalation schedule.{{r|coskun2022}}
+44
43== References ==45== References ==
44{{reflist}}46{{reflist}}
53* [[Survodutide]]55* [[Survodutide]]
54* [[Peptide aggregation]]56* [[Peptide aggregation]]
+57* [[Hypoglycaemia]]
5558
56{{DEFAULTSORT:Glucagon}}59{{DEFAULTSORT:Glucagon}}